Odds of diabetic kidney disease higher in obese teens receiving medical therapy versus bariatric surgery for T2DM
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
Sweden’s lower HbA1c target values not linked to further organ protection
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Machine learning algorithms can aid in assessment of renal histopathology
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors